Advances in Hematology / 2016 / Article / Tab 3

Review Article

Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow—Review of Published Literature

Table 3

Transplant outcomes.

ReferenceEngraf. failureMed. days to neut./PLT eng.aGVHD
II–IV/III-IV
cGVHDNRM Relapse EFS/PFSOS

O’Donnell et al., 2002 [24]20%
Cohort 2
15/14 46%/23%1/10 limited1/10 died of GVHD4/10 cohort 2 relapsedAt med. f/u 6 mo. 5/10 in CRAt med. f/u 6 mo. 6/10 (cohort 2) alive

Luznik et al., 2008 [25]13%15/2434%/6%Ext. 5% in 2 doses of CY versus 25% in one dose of Cy1 y 15%1 y 51%2 y EFS 26%2 y 36%

Symons et al., 2011 [26]4%25/3214%/7.3%13%100 D 12%1 y 66% poor risk
1 y 13% in CR
1 y 23.5%1 y 40%

Brunstein et al., 2011 [27]2%16/2432%/01 y 13%1 y 7%1 y 45%1 y PFS 48%1 y 62%

Pingali et al., 2014 [28]4.7%18/NA32.6%/7.8%21.3%/Ext. 10%25%3 y 30.1%3 y PFS 42.3%1 y OS 64%
Median OS for 1st SCT 25.6 mo.
2nd SCT 6.5 mo.

Solomon et al., 2012 [29]0%16/2730%/10%35%/severe 5%1 y 10%1 y 40%1 y DFS 50%1 y 69%

Raiola et al., 2013 [30]6%18/2312%/6%26%/Ext. 06 mo. 18%18 mo. 22%DFS 18 mo. 51%18 mo. 62%

Raj et al., 2014 [31]4%17/21II 35%
III 8%
IV 0%
18% @ 2 y
2 severe cases
1 y 17%2 y 28%2 y 51%2 y 48%

Bhamidipati et al., 2014 [32]6%15/18All grades 53%/17%8% @ 2 y
Ext. only in 1 patient
1 y 17%1 y 38%1 y 53%1 y 62%

Castagna et al., 2014 [33]NABM 21/2925%/3%13%2 y 19% 1 y 22%2 y PFS 62%2 y 68%
NAPB 20/2733%/14%13%1 y 12%

Solomon et al., 2015 [34]016/2543%/23%56%/Ext. 10%2 y 3%2 y 24%2 y DFS 73%2 y 78%

Bradstock et al., 2015 [35]015/18I–III 55.1%
No IV
28.6%6 mo. 02 y 43.9%2 y EFS 44.9%2 y 52.7%
13%16/24I–III 48.5%
No IV
32.3%6 mo. 02 y 23.5%2 y EFS
63.6%
2 y 83.4%

Gayoso et al., 2013 [36]NA18/2733%/14%24%/Ext. 12%6 mo. 19%NA1 y EFS
48%
1 y 60%

Sugita et al., 2015 [37]13%
(0 in no h/o SCT; 31% in h/o SCT)
19/3523%/3%15%/none severe1 y 23%1 y 45%1 y DFS
34%
1 y 45%

aGVHD, acute graft versus host disease; cGVHD, chronic graft versus host disease; CR, complete remission; Cy, cyclophosphamide; D, day; DFS, disease-free survival; Engraf., engraftment; EFS, event-free survival; Ext., extensive; mo., months; neut., neutrophils; NRM, nonrelapse mortality; OS, overall survival; PFS, progression-free survival; PLT, platelets; y, year.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.